Jay Levine is a partner in the firm’s Washington, D.C. litigation department. His practice is concentrated in complex litigation, particularly antitrust and consumer protection matters.
Jay has extensive litigation experience in a variety of industries, particularly health care, pharmaceuticals and consumer products. Over the past few years, he has represented pharmaceutical companies in several antitrust and competition-related actions, many of which involved issues not previously litigated. Jay also was a senior member of the trial team that defended against a challenge by the Federal Trade Commission to enjoin the merger of two suburban Chicago hospitals. That case, In the matter of Evanston Northwestern Healthcare Corp., presented many novel issues. He played a critical role in United States v. Long Island Jewish Medical Center, the Department of Justice's attempt to prevent the merger of two New York health systems. After a six-month investigation and one-month trial, the court denied the government’s request.
A significant portion of Jay’s practice focuses on counseling clients engaged in mergers and acquisitions. He regularly counsels such clients before the Federal Trade Commission and the Antitrust Division of the Department of Justice, as well as before states’ antitrust authorities. Over the past few years, he has successfully obtained clearance from the antitrust authorities in a number of competitively sensitive transactions. These transactions occurred in a variety of industries, including food and beverage distribution, logistics, consumer products, fashion and health care. Jay also regularly advises private equity funds concerning their strategic initiatives.
In addition to litigation and merger defense, Jay counsels clients on a wide range of domestic and foreign antitrust and trade regulation matters, including pricing and distribution restrictions, joint ventures, exclusive dealing, price discrimination and advertising matters.
Jay regularly speaks on antitrust, litigation, and intellectual property issues, and can be followed on Twitter @JayLLevine
. He is also a contributing author to the firm's Technology Law Source